Insulin pump based expert system

Information

  • Patent Grant
  • 11576594
  • Patent Number
    11,576,594
  • Date Filed
    Wednesday, September 4, 2019
    4 years ago
  • Date Issued
    Tuesday, February 14, 2023
    a year ago
Abstract
An apparatus including a controller can determine a rate of change of a blood glucose level of a subject from blood glucose data and determine if there is a risk of the blood glucose level going high or low.
Description
TECHNICAL FIELD

The field generally relates to patient insulin management devices and, in particular, but not by way of limitation, to systems, devices and methods for managing insulin therapy.


BACKGROUND

People who suffer from diabetes require insulin to keep their blood glucose level as close as possible to normal levels. It is essential for people with diabetes to manage their blood glucose level to within a normal range. Complications from diabetes can include heart disease (cardiovascular disease), blindness (retinopathy), nerve damage (neuropathy), and kidney damage (nephropathy). Insulin is a hormone that reduces the level of blood glucose in the body. Normally, insulin is produced by beta cells in the pancreas. In non-diabetic people, the beta cells release insulin to satisfy two types of insulin needs. The first type is a low-level of background insulin that is released throughout the day. The second type is a quick release of a higher-level of insulin in response to eating. Insulin therapy replaces or supplements insulin produced by the pancreas.


Conventional insulin therapy typically involves one or two injections a day. The low number of injections has the disadvantage of allowing larger variations in a person's insulin levels. Some people with diabetes manage their blood glucose level with multiple daily injections (MDI). MDI may involve more than three injections a day and four or more blood glucose tests a day. MDI offers better control than conventional therapy. However, insulin injections are inconvenient and require a diabetic person to track the insulin doses, the amount of carbohydrates eaten, and their blood glucose levels among other information critical to control.


It is important for a diabetic person to be treated with the proper amount of insulin. As discussed previously, high blood sugar can lead to serious complications. Conversely, a person with low blood sugar can develop hypoglycemia. Ideally, insulin therapy mimics the way the body works. An insulin pump is one way to mimic the body's insulin production. An insulin pump can provide a background or basal infusion of insulin throughout the day and provide a quick release or bolus of insulin when carbohydrates are eaten. If a person develops high blood sugar, a correction bolus can be delivered by the pump to correct it. While insulin pumps improve convenience and flexibility for a diabetic person, they can be sophisticated devices. Some insulin pumps can be difficult to program. Proper use of an insulin pump requires a user to go through a learning curve to properly treat their diabetes using the insulin pump.


SUMMARY

This document discusses, among other things, devices and methods for managing insulin therapy. A device example includes a pump configured to deliver insulin, an input configured to receive blood glucose data, a user interface, and a controller communicatively coupled to the pump, the input, and the user interface. The controller includes a blood glucose data module to compare the blood glucose data to a target blood glucose level for an insulin pump user. The controller is configured to present a question related to the blood glucose level via the user interface when the blood glucose level is different than the target blood glucose level, receive a response to the question via the user interface, and present a recommended user action based at least in part on the response.


A method example includes receiving blood glucose data into a device that includes an insulin pump, presenting a question related to a blood glucose level of an insulin pump user when determining, from the blood glucose data, that the blood glucose level is different from a target blood glucose level, receiving at least one response to the question into the insulin pump device, and presenting a recommended action for a user to take based, at least in part, on the response.


A system example includes a first device and a second device. The first device includes a pump configured to deliver insulin, an input that includes a communication port configured to receive blood glucose data, a user interface, and a controller communicatively coupled to the pump mechanism, the input, and the user interface. The controller includes a blood glucose data module configured to compare the blood glucose data to a target blood glucose level for an insulin pump user. The controller is configured for presenting a question related to the blood glucose level when the blood glucose level is different from a target blood glucose level, receiving a response to the question via the user interface, and presenting a recommended action for the user to take based at least in part on the response. The second device includes a user interface, a processor that includes a rule development module configured for developing the rule via the user interface, and a communication port configured to communicate the rule to the first device.


This summary is intended to provide an overview of the subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the subject matter of the present patent application.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate portions of a device that includes an insulin pump.



FIG. 2 is a block diagram of an example of portions of an insulin pump device.



FIG. 3 shows an example of a method for managing insulin therapy.



FIG. 4 shows a portion of an example of a decision tree to determine one or more questions for the user of an insulin pump device.



FIG. 5 shows an example of a portion of a system that provides an environment to customize a rule for an insulin pump device.





DETAILED DESCRIPTION

The following detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments, which are also referred to herein as “examples,” are described in enough detail to enable those skilled in the art to practice the invention. The embodiments may be combined, other embodiments may be utilized, or structural, logical and electrical changes may be made without departing from the scope of the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined by the appended claims and their equivalents.


In this document, the terms “a” or “an” are used, as is common in patent documents, to include one or more than one. In this document, the term “or” is used to refer to a nonexclusive or, such that “A or B” includes “A but not B,” “B but not A,” and “A and B,” unless otherwise indicated. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.



FIGS. 1A and 1B illustrate portions of a device 100 that includes an insulin pump. The device 100 includes a cassette or cartridge of insulin. The cartridge is connectable to infusion tubing 140 connectable to a patient such as by a Luer lock 145 or infusion set 142. The device 100 includes a display 102 and a user interface that may include the display 102 and include one or more keys 104. Because proper use of an insulin pump requires a user to go through a learning curve to properly treat their diabetes using the pump, it is desirable for a pump to provide assistance to the user, whether the user is a diabetic patient, a caregiver, or a clinician. Providing an expert system in an insulin pump device will provide assistance to the user to effectively treat their diabetes using the insulin pump device.



FIG. 2 is a block diagram of an example of portions of an insulin pump device 200. The insulin pump device 200 includes a pump 205 or pump mechanism to deliver insulin to a subject, such as a positive displacement pump for example. The insulin pump device 200 also includes a user interface 210, an input 215, and a controller 220. The user interface 210 receives manual input from a user and may include one or more pushbuttons or a keypad. The user interface 210 may include a display 202 to provide instructions to the user. The user of the device may be a clinician or a diabetic patient. The display 202 may include a touch-screen.


The input 215 is configured to receive blood glucose data of a patient or subject. The input 215 may be coupled to a blood glucose monitor (GM) included in the insulin pump device 200 or the input 215 may include a communication port to receive the blood glucose data from a second separate device. In some embodiments, the communication port 235 is a wireless communication port configured to receive the blood glucose data from the separate device wirelessly. If the GM is a continuous GM, the continuous GM automatically collects the sampled blood glucose data in real time. The insulin pump device 200 may receive the blood glucose in real time as it is obtained, or communicated at a later time. If the data is communicated at a later time, a timestamp may be included with the blood glucose data to indicate at what time the data was collected. In some embodiments, the input 215 is coupled to the user interface 210, and the user may manually input the data into the insulin pump device 200 through a keypad included in the user interface 210.


In some examples, the GM may require a prompt from the user to begin a blood glucose data measurement to obtain the blood glucose data. For example, the GM may require diabetes test strips to take a blood glucose measurement. The controller 220 recurrently presents a prompt to the user to begin a blood glucose measurement using the GM and obtain blood glucose data. In certain examples, the prompt is presented periodically. The prompt may be presented via the display 202. The prompt may be presented by activating a light emitting diode (LED) included in the insulin pump device 200. In some examples, the prompt is presented by audibly such as by a transducer or by a speaker instructing the user. The user then provides a new test strip to the GM when prompted during the correction factor test. In another example, the GM may include a drum of diabetes test strips and the user advances the drum to a fresh or unused test strip when prompted by the controller 220.


If the insulin pump device 200 includes a continuous GM, the input 215 may be coupled to blood glucose sensor circuit. The blood glucose sensor circuit includes a blood glucose sensor to produce a blood glucose signal representative of a blood glucose level of the patient. The blood glucose sensor may sense blood glucose concentration from blood or interstitial fluid. The blood glucose sensor circuit may include a sensor interface circuit to sample the blood glucose signal and may provide additional signal processing such as filtering or amplification for example. The blood glucose sensor circuit may provide sampled blood glucose data to the input 215. A description of a blood glucose sensor circuit can be found in Steil et al., U.S. Pat. No. 6,558,351, filed Jun. 1, 2000.


The controller 220 is operatively coupled to the pump mechanism 205, the input 215, and the user interface 210. The controller 220 can be implemented using hardware circuits, firmware, software or any combination of hardware, firmware and software. Examples, include a microcontroller, a logical state machine, and a processor such as a microprocessor, application specific integrated circuit (ASIC), or other type of processor. The controller 220 is configured to perform or execute a function or functions. Such functions correspond to modules, which are software, hardware, firmware or any combination thereof. Multiple functions are performed in one or more modules.


The controller 220 monitors the blood glucose data of the subject. The controller 220 includes a blood glucose data module 230. The blood glucose data module 230 uses the blood glucose data to determine whether a blood glucose level of the subject is different from a target blood glucose level. The target blood glucose level may include a specified range of blood glucose levels and the blood glucose data module 230 may determine whether the blood glucose data indicates the blood glucose of the pump user is outside of a specified range of blood glucose levels. Being outside of a range may include having a blood glucose level that is too high or too low. The blood glucose data module 230 may determine whether a blood glucose level is above an acceptable range of higher blood glucose level, or below an acceptable range of low blood glucose levels. The target or range may be stored in memory and be a programmable parameter available to the blood glucose data module 230. A clinician would specify the range of blood glucose levels for the patient. The range would depend on various factors for the patient such as weight, age, and level of activity of the patient for example.


If the blood glucose data module 230 determines that the blood glucose level of the subject is different from the target or the specified range of blood glucose levels, the controller 220 presents one or more questions related to the blood glucose level via the user interface 210. Preferably, the question is presented using the display 202. However, in some examples, the question may be presented audibly. Presenting the question audibly may be useful if the insulin pump user has difficulty seeing the display 202. The questions are designed to help a user to properly treat their diabetes using the insulin pump device 200 and even by programming the insulin pump device 200. In some examples, the controller 220 presents different questions according to different blood glucose levels. For example, the controller 220 may present different questions according to whether the blood glucose level of the patient is above 200 mg/dl, or above 300 mg/dl, or above 400 mg/dl. The clinician may program the different levels into the insulin pump device 200.


The user responds to the question through the user interface 210. Based at least in part on one or more responses, the controller 220 displays at least one recommended action for the user to take. As is discussed below, the recommended action may involve various user actions such as troubleshooting the insulin pump device 200, delivering insulin using the insulin pump device 200, initiating a measurement or test using the insulin pump device 200, or making lifestyle changes for example. In some examples, the recommended action for display may include contacting a physician. In some examples, the recommended action may be different according to the blood glucose level of the patient. For example, the controller 220 may present different actions according to whether the blood glucose level of the patient is above 200 mg/dl, or above 300 mg/dl, or above 400 mg/dl.


If the question is presented using a display 202, the device may include an alarm circuit 245 coupled to the controller 220 to draw the attention of the user to the display 202. The alarm circuit 245 may include an audible alarm, a visual indication such as a flashing light or flashing icon on the display, or the alarm circuit may mechanically vibrate the insulin pump device to draw attention of the user. The controller 220 activates the alarm circuit 245 if it is determined that the blood glucose level of the subject is outside of the specified range of blood glucose levels.



FIG. 3 shows an example of a method 300 for managing insulin therapy. At block 305, blood glucose data is received into an insulin pump device 200. At block 310, at least one question related to a blood glucose level of a patient is presented when determining, from the blood glucose data, that the blood glucose level is outside of a range of blood glucose levels. The question may be presented on a display 202 included with the insulin pump device 200, or the question may be transmitted to a second device for display, such as a computer for example. This may be useful if a display 202 on the insulin pump device 200 is difficult for the user to read. In some examples, the second device presents the question audibly. The insulin pump and the second device may communicate wirelessly such as by radio frequency (RF) or infrared red (IR) communication. At block 315, at least one response to the question is received into the insulin pump device 200. The response may be received through a user interface. At block 320, at least one recommended action is presented for a user to take based, at least in part, on the response. The action may be presented audibly or visually, such as by a display for example.


Returning to FIG. 2, in some embodiments, the controller 220 includes a rule module 225 to apply at least one rule to the blood glucose data to determine the question to be presented. In some embodiments, the rule includes a decision tree. FIG. 4 shows a portion of an example of a decision tree 400 to determine one or more questions for the user of the insulin pump device 200. In certain examples, the decision tree 400 may implemented with a series of IF-Then logic statements. The controller 220 traverses the decision tree 400 using various information such as the blood glucose data, responses from the user, or other data. If the blood glucose is high, the left portion of the decision tree 400 is traversed at block 405. The controller 220 may display a recommended action, such as the user taking a correction bolus at block 410, before asking one or more questions. If the blood glucose is low, the right portion of the decision tree 400 is traversed at block 415. The controller 220 may display a recommended action, such as the user eating food at block 420 before asking one or more questions. The controller 220 may display a picture or icon of food when making the recommendation.


In some examples, the rule module 225 applies the rule to the blood glucose data and to at least one user response to the question to determine the recommended action for display. For example, using the decision tree 400, if the blood glucose level is high, the controller 220 may display a question asking if the infusion site is red at block 425. If the user interface 210 receives a response from the user that the site is red, the controller 220 may display a recommendation that the user change the infusion site at block 430.


In some embodiments, the rule module 225 may include a look-up table stored in a memory. For example, if the blood glucose is low, the look up table may include a question as to whether the patient had a high activity level. If the user interface 210 receives a response that the activity level was high, the look up table includes a recommended action corresponding to a table entry for low blood glucose and high activity. The table entry may include a recommended action that the patient eat before the activity or lower a programmable basal rate of insulin before or during the activity. The table may include multiple dimensions to take into account multiple factors, responses, or other data. In some examples, the rule module 225 assigns weights to corresponding table entries. For example, receiving a response that the infusion set has visible blood may by weighted as a stronger indication to change the infusion site than if a response is received that the infusion site is red. In some examples, the rule module 225 uses one or more fuzzy logic rules to determine the question for display and any recommended action. The fuzzy logic rules may be used to blend any weighted questions, responses, or actions. In some examples, the rule module 225 uses a rule involving application of artificial intelligence methods to determine the questions and the actions to be presented.


In some examples, the rule module 225 may apply the rule to the blood glucose data and present a recommendation that the user initiate at least one blood glucose measurement. The measurement may be made using a second separate device that includes a GM, or the action may recommend making the measurement with the insulin pump device 200 if the device includes a GM.


Note that application of the rule by the rule module 225 may result in a series of questions displayed, responses by the user, and recommend actions. For example, the insulin pump device 200 may receive an indication that a recommended action was taken. The rule module 225 may apply the rule to the blood glucose data, the response to the question, and the indication that the action was taken to determine at least one of a further question and a further recommended action to be presented.


In some examples, the rule module 225 may apply the rule to the blood glucose data and present a recommendation that the user initiate a basal rate test. Basal rate refers to a type of twenty-four hour background infusion of insulin by an insulin pump that mimics the continuous background release of insulin from a normal pancreas. It is the rate of insulin delivery the patient normally needs independent of the consumption of meals. If the basal rate is inappropriate, blood glucose concentration levels may result that are out of a recommended or desired range. An insulin pump user may go through several iterations of trial and error before finding appropriate basal rates. Because a patient's basal insulin needs may change over time, such as with weight change or with a change in fitness level, basal rate testing may be performed periodically to ensure that an appropriate basal rate is being delivered by an insulin pump. Based on the blood glucose level, the rule module 225 determines that a recommendation to run a basal rate test (by either the insulin pump device 200 or a separate device) should be presented (such as by display). As a result of the basal rate test, the controller may display a recommendation to change a programmable basal rate pattern or profile of the insulin pump device 200. Descriptions of devices and methods that perform a basal rate test are found in Blomquist et al., “Basal Rate Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/685,617, filed Mar. 13, 2007, which is incorporated herein by reference.


In some examples, the rule module 225 may apply the rule to the blood glucose data and present a recommendation that the user initiate a carbohydrate ratio test if the blood glucose level is outside a desired range. A carbohydrate ratio refers to the amount of carbohydrates covered by a unit of insulin. It is sometimes referred to as a carbohydrate factor, or carb factor, and is typically specified as grams of carbohydrates per unit of insulin. The insulin pump device 200 may use the carbohydrate ratio to automatically determine a carbohydrate insulin bolus amount required to match a number of carbohydrates ingested by the patient, or at least to keep post-meal blood glucose within a range that is healthy for a patient. For example, the patient may plan to eat seventy grams of carbohydrates. If the carbohydrate ratio is ten grams of carbohydrates per unit of insulin, the insulin pump device 200 would determine that seven units of insulin are required to cover the carbohydrates.


The appropriate carbohydrate ratio may vary from person to person, yet it is important for an insulin pump to use an appropriate carbohydrate ratio. If a carbohydrate ratio is too small, the pump may determine a carbohydrate bolus that is too large for the carbohydrates consumed. This may cause a low blood glucose level within a few hours of the carbohydrate bolus (e.g., the blood glucose level drops below 70 mg/dl). If a carbohydrate bolus is too large, the insulin pump device 200 may determine a carbohydrate bolus that is too small for the carbohydrates consumed. This may cause a high blood glucose level within a few hours of a carbohydrate bolus. Based on the blood glucose level, the rule module 225 determines that a recommendation to run a carbohydrate ratio test should be presented. As a result of the carbohydrate ratio test, the controller 220 may present a recommendation to change a carbohydrate insulin bolus pattern or profile delivered by the insulin pump device 200. For example, the controller 220 may recommend a carbohydrate bolus pattern that includes an extended carbohydrate bolus or a combination bolus. Descriptions of devices and methods that perform a carbohydrate ratio test are found in Blomquist, “Carbohydrate Ratio Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/679,712, filed Feb. 27, 2007, which is incorporated herein by reference.


In some examples, the rule module 225 may apply the rule to the blood glucose data and present a recommendation that the user initiate a correction factor test. A correction factor refers to the amount in drop in blood sugar, or blood glucose, for one unit of insulin. It is measured in milligrams per deciliter (mg/dl) per unit in the U.S. and in millimoles (mmol) per unit in other countries. The insulin pump device 200 may use the correction factor to automatically determine a bolus amount required for a high reading or a reduction in a meal bolus for a below-target reading. The insulin pump device 200 may also use the correction factor to calculate the amount of carbohydrates a patient should eat to bring low blood sugar up to a target blood sugar level. An appropriate correction factor brings a high blood glucose reading down using an automatically determined correction bolus without a risk of going low.


The appropriate correction factor varies from person to person. It is important for an insulin pump to use an effective correction factor. If a correction factor for a pump is set too high, the blood glucose may not actually be dropping as much as estimated and could lead to high blood glucose levels. If the correction factor is set too low, a correction bolus may provide too much insulin and result in a low blood glucose level. As a result of the carbohydrate ratio test, the controller 220 may display a recommendation to change an insulin correction bolus pattern or profile, such as to include an extended bolus or a combination bolus for example. Descriptions of devices and methods that perform a carbohydrate ratio test are found in Blomquist et al., “Correction Factor Testing Using Frequent Blood Glucose Input,” U.S. patent application Ser. No. 11/626,653, filed Jan. 24, 2007, which is incorporated herein by reference.


In some embodiments, the rule module 225 may receive an updated or new rule or a modification to the rule. In certain embodiments, the insulin pump device 200 includes a communication port 235 coupled to the input 215. The communication port 235 receives the rule into the insulin pump device 200 from a second separate device. In some examples, the communication port 235 is a wireless port and receives the rule wirelessly. The second device may be a computer or a personal data assistant (PDA). The second device may provide an environment (e.g., such as through software) for a diabetes professional, clinician, or other caregiver to customize the rule. In some examples, the environment allows the clinician to customize a decision tree or look up table.



FIG. 5 shows an embodiment of a portion of a system 500 that provides an environment to customize rules in the rule module 225. The system 500 includes an insulin pump device 200 and a computing device 550. The insulin pump device 200 includes a communication port 235 to communicate information with the computing device 550. The communication port 235 shown is a wireless port that communicates wirelessly with the computing device 550, such as a radio frequency (RF) port or infrared (IR) port for example. The communication port 235 may receive blood glucose data from a third device, such as a GM for example. In certain examples, the insulin pump device 200 receives the blood glucose data from a GM when the GM is communicatively coupled to the communication port 235. The insulin pump device 200 is able to communicate information with the computing device 550 when the GM is not communicatively coupled to the insulin pump device 200. In some examples, the communication port 235 may be a wired port, such as a serial port for example, to communicate with the computing device 550.


The computing device 550 may be a personal computer (PC), laptop computer, or a personal data assistant (PDA). The computing device 550 includes a user interface 555 that includes a display and may include at least one of a keyboard or keypad and a computer mouse. The computing device 550 also includes a processor 560 communicatively coupled to the user interface 555. The processor 560 can be a microprocessor, application specific integrated circuit (ASIC), or other type of processor.


The processor 560 includes a rule development module 565 that provides doctors or clinical experts the ability to develop and generate a new rule or rule set or modify rules via the user interface 555. The computing device 550 includes software that provides a flexible framework to create or modify rules such as by updating a graphical decision tree, a multidimensional table, or other type of logical rule. The software may be included in a computer readable medium, such as a compact disc (CD) for example, or the software may be downloaded to the computing device 550 from remote storage, such as from a server for example. The rule development module 565 develops a rule to be applied to the blood glucose data received into the insulin pump device 200, and may develop a rule that is also applied to at least one of physiologic data, demographic data, patient lifestyle data, insulin delivery history data, and blood glucose history data to generate a recommended action. The computing device 550 includes a communication port 535 to communicate information with the insulin pump device 200. The computing device 550 uses the communication port 535 to communicate the rule to the insulin pump device 200.


Once a rule is developed, the doctor or clinical expert could publish or otherwise share a rule or set of rules. In some embodiments, rule sets can be stored in remote storage, such as a server for example. The computing device 550 may be connected to a communication network, such as the internet or a cell phone network for example. A doctor or clinical expert may download a rule or rule set from the remote storage and either download the rule set directly from the computing device 550 into the insulin pump device 200 or modify the rule or rule set before downloading the modified rule or rule set to the insulin pump device 200.


Returning to FIG. 2, in some embodiments, the user interface 210 and the input 215 receive modifications to the rule that are entered into the insulin pump device 200 manually by the user via the user interface 210. For example, the user may step through the rule with the aid of the display 202. The user may then alter the rule with a keypad included in the user interface 210. For example, the user may enter a new look up table entry using the key pad, or add another branch to a decision tree or edit a branch of the decision tree. In certain embodiments, an entire new rule or rule set is entered manually into the insulin pump device 200 via the user interface 210.


In some embodiments, the insulin pump device 200 stores data to track effectiveness of a new rule or modified rule. For example, the insulin pump device 200 may track the number of times the blood glucose level of the patient returned to the target blood glucose level or to within the target range of levels after application of the rule. The effectiveness may be displayed as a percentage or as X successes out of Y applications on either a display 202 of the insulin pump or uploaded and displayed on a separate device, such as the computing device 550 in FIG. 5 for example.


If a rule or rule set is downloaded into multiple devices, the effectiveness of the rule set for multiple device may be tracked. The stored data related to the effectiveness may be uploaded to a remote server and the server tracks the overall effectiveness of the rule over the multiple devices. The overall effectiveness may be useful to a clinician in determining whether to download a particular rule or rule set to the insulin pump device 200.


In some embodiments, controller 220 determines a rate of change of a blood glucose level of the subject from the blood glucose data. For example, the controller 220 may determine that the blood glucose concentration level is increasing or decreasing at a rate of 2 to 4 mg/dl/min (milligrams per deciliter per minute). The rule module 225 may apply one or more rules to the rate of change of a blood glucose level to determine at least one of a question for display or one or more recommended actions for display. For example, the blood glucose level of the user may not be high, but the rate of change of blood glucose may be increasing at such a rate to indicate there is a risk of the blood glucose level going high. Conversely, the blood glucose level of the user may not be below a blood glucose target, but the rate of change of blood glucose may be decreasing at such a rate to indicate there is a risk of the blood glucose level going low.


In some examples, the rule module 225 may apply the rules to at least one of the blood glucose data, the rate of change of blood glucose data, and a response to a question to determine a subsequent question or recommended action for display by the controller 220. For example, if the blood glucose level is high and increasing at a certain rate, the rule module 225 may apply the rule to determine that a recommended action to take a correction bolus should be presented before presenting a question. In another example, if the blood glucose level is high and decreasing at a certain rate, the rule module 225 may apply the rule to determine that a recommended action to take a correction bolus should not be displayed and proceed to displaying a question such as whether the patient ate something where it was difficult to estimate the carbohydrates.


According to some embodiments, the controller 220 may display a recommendation that the patient consume carbohydrates if the blood glucose level is low or there is a risk of blood glucose level going low. In some examples, the memory 240 may store a database of food options in association with a known amount of carbohydrates. The recommended action presented by the controller 220 may include displaying a food option for consumption that is included in the database.


In some embodiments, the controller 220 determines an amount of carbohydrates for the patient to consume and presents a food option accordingly. For example, assume that the blood glucose level of a patient is 40 mg/dl below a desired range of blood glucose levels. The correction factor is stored in the insulin pump device 200 and is 1 unit per 80 mg/dl. The controller 220 determines that −0.5 unit of insulin (−40/80) is required to bring the blood glucose level back to the target level or range. Further assume that the carbohydrate ratio of the patient is 20 grams of carbohydrates per unit of insulin (20 g/u). The controller 220 multiplies the amount of insulin by the carbohydrate ratio to determine that the patient should eat 10 grams of carbohydrates [(0.5)(20)]. The insulin calculation module 125 may take into account additional factors such as the health status of the patient and the activity level of the patient in recommending the carbohydrate amount. In some example, the food option may be displayed using an icon or picture of food.


According to some embodiments, the input 215 receives physiologic data into the insulin pump device 200 from a separate second device. The data may be received through the input 215 or another input. In some embodiments, the insulin pump device 200 receives the physiologic data through a communication port 235. In some examples, the insulin pump device 200 receives the physiologic data through the same communication port 235 that receives the blood glucose data. In some examples, the second device includes a temperature monitor and the physiologic data includes a patient temperature. In some examples, the second device includes an activity monitor and the physiologic data includes an indication of a level of patient activity.


The rule module 225 may apply one or more rules to the physiologic data to determine a question for display. The rule module 225 may apply one or more rules to the physiologic data and a response to the question to determine one or more recommended actions for display. In some examples, the rule module 225 may apply one or more rules to the physiologic data, the blood glucose data, at least one question response to determine a question or recommended action for display. The controller 220 displays the questions and recommended actions.


In some embodiments, the insulin pump device 200 includes a memory 240 communicatively coupled to the controller 220. The memory 240 may store demographic data of the subject. The demographic data includes such information as a patient's weight, age, and gender for example. The demographic data may be received from a second device or through the user interface 210. The rule module 225 may apply one or more rules to the demographic data to determine a question to be presented. The rule module 225 may apply one or more rules to the demographic data and a response to the question to determine and/or adjust one or more recommended actions. In some examples, the rule module 225 may apply one or more rules to the demographic data, the blood glucose data, at least one question response to determine a question or recommended action for display.


In some embodiments, the controller 220 adjusts the questions and recommended actions based on the demographic data. For example, the controller 220 may use a different set of questions and recommended actions when the demographic data indicates that the patient is a child than when the demographic data indicates the patient is an adult.


In some embodiments, the memory 240 may store lifestyle data of the subject. The lifestyle data includes such information as whether a patient tends to eat high glycemic index foods, drinks alcohol, smokes, eats a bedtime snack, a health status of the patient, whether the patient is typically under stress, whether the patient tends to be active, and the amount time the patient spends exercising, for example. The lifestyle data may be received from a second device or entered through the user interface 210. The rule module 225 may apply one or more rules to the lifestyle data to determine a question for display. The rule module 225 may apply one or more rules to the lifestyle data and a response to the question to determine one or more recommended actions for display. In some examples, the rule module 225 may apply one or more rules to the lifestyle data, the blood glucose data, at least one question response to determine a question or recommended action for display.


A recommended action may include a change to at least one aspect of the patient's lifestyle, such as to skip the bedtime snack or to eat lower glycemic index meals, for example. In some examples, the recommended action may include recommending patient training. In certain examples, the insulin pump device 200 may present a recommendation that the patient be trained in carbohydrate counting. In certain examples, the insulin pump device 200 may recommend that the patient be trained in managing their exercise. In certain examples, the insulin pump device 200 may recommend that the patient be trained in using the insulin pump when the patient is sick. In certain examples, the insulin pump device 200 may recommend that the patient be trained in proper infusion site care.


In some embodiments, the memory 240 may store insulin delivery history data of the patient. Insulin delivery history data may include a time duration since the last meal bolus, how long since the cartridge was changed, and whether there have been any recent changes to programming parameters and what those changes were for example. The rule module 225 may apply one or more rules to the insulin delivery history data to determine a question to be presented. The rule module 225 may apply one or more rules to at least one of the insulin delivery history data, the blood glucose data, and a response to a question to determine one or more recommended actions.


In some embodiments, the memory 240 may store blood glucose history data of the subject. Blood glucose history data may include blood glucose data from a previous time period, such as two hours or 24 hours in the past for example. The data may be received from a GM included in the insulin pump device 200 or from a GM included in a separate device. In some examples, the blood glucose history data may be received from a separate computing device such as a PC, laptop, or PDA configured to communicate with the insulin pump device 200. The controller 220 may generate a prompt to download blood glucose history data from the second separate device, such as a prompt on a display 202, an LED prompt, or an audible prompt. The rule module 225 may apply one or more rules to the blood glucose history data to determine a question to be presented. The rule module 225 may apply one or more rules to at least one of the blood glucose history data, the blood glucose data collected in real time, and a response to a question to determine one or more recommended actions.


The patient may experience trouble with the insulin pump device 200 itself. According to some embodiments, the recommended action presented by the controller 220 includes actions for troubleshooting the insulin pump device 200. If the blood glucose level is low, the recommended actions may include checking or changing the insulin cartridge, the infusion set, the infusion set tubing, and/or the infusion site. For example, if the insulin pump device 200 stores the time since the cartridge was changed, the rule module 225 may determine that it is time for a new cartridge and display instructions to check whether the cartridge is low or change the cartridge. If it has been a short time since the cartridge was changed, the rule module 225 may eliminate the cartridge as the problem and display instructions to check or change the infusion set or the infusion site.


In another example, the user may respond that the cartridge was checked. The rule module 225 may apply the rule to the blood glucose level and the response and eliminate the cartridge as the problem. The insulin pump device 200 and the user may then step through response and actions that instruct the user to troubleshoot the infusion set and site. The controller 220 may also present a recommendation to change the type of insulin. For example, the rule module 225 may determine that the delay for uptake is too slow and recommend that the patient use a type of insulin with faster uptake. The controller 220 may also present a recommendation to change an insulin pump executable program and to see a diabetes professional. The controller may present a question whether the infusion set has visible blood and recommend that the infusion site be changed if there is visible blood. In some examples, the controller 220 may display a device error code and a recommendation to see the diabetes professional rather than present instructions to the user or patient that the pump program should be changed. The diabetes professional interprets the error code to determine the recommended action.


According to some examples, the blood glucose data module 230 may determine from the blood glucose data that a blood glucose level of the subject is at a target blood glucose level or within a specified range of blood glucose levels. The rule module 225 may determine one or more recommend actions for the patient to take that are related to maintaining normoglycemia. The rule module 225 may apply the rule to the blood glucose data and at least one of the physiologic data, the demographic data, the lifestyle data, the blood glucose history data, the insulin delivery history data, question responses, and previous actions taken to make the recommendation. The controller 220 displays the recommended action. For example, the controller 220 may ask lifestyle questions when blood glucose data is in the normoglycemic range. The controller 220 may aggregate insulin pump data and answers to the questions from various times when the blood glucose data values were in range and help the patient identify lifestyle or therapy patterns that promote good glycemic control.


It is to be understood that the above description is intended to be illustrative, and not restrictive. For example, the above-described embodiments (and/or aspects thereof) may be used in combination with each other. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled. In the appended claims, the terms “including” and “in which” are used as the plain-English equivalents of the respective terms “comprising” and “wherein.” Also, in the following claims, the terms “including” and “comprising” are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms “first,” “second,” and “third,” etc. are used merely as labels, and are not intended to impose numerical requirements on their objects.


The Abstract of the Disclosure is provided to comply with 37 C.F.R. § 1.72(b), requiring an abstract that will allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it can be seen that various features are grouped together in a single embodiment for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed embodiments require more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed embodiment. Thus the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own.

Claims
  • 1. A system comprising: a pump configured to deliver insulin;an input configured to receive sensor glucose data representative of a blood glucose level of a user from a continuous glucose monitor via a wireless connection; anda controller communicatively coupled to the pump and the input, the controller configured to: monitor the sensor glucose data from the continuous glucose monitor;determine a rate of change of the blood glucose level and a current glucose level of the user from the sensor glucose data;compare the current glucose level of the user and the rate of change of the blood glucose level to a predetermined high glucose level;determine that a correction bolus should be delivered when the current glucose level of the user is not over the predetermined high glucose level but the rate of change indicates that there is a risk of the user going over the predetermined high glucose level in the future;automatically calculate the correction bolus; andcause the pump to deliver the correction bolus to the user.
  • 2. The system of claim 1, wherein the controller is configured to automatically deliver the correction bolus.
  • 3. The system of claim 1, wherein the controller is further configured to present a recommendation to deliver the correction bolus on a user interface and to deliver the correction bolus only after receiving a confirmation in response to the recommendation.
  • 4. The system of claim 1, wherein the controller is configured to determine, based on a current blood glucose level of the user and the rate of change of the blood glucose level, that a correction bolus should be delivered if the blood glucose level is high and increasing at a certain rate.
  • 5. The system of claim 1, wherein the controller is further configured to provide a notification to the user regarding the correction bolus.
  • 6. The system of claim 1, wherein the controller, the input and the pump are part of a common device.
  • 7. The system of claim 1, wherein the controller and the input are part of a handheld device that is separate from the pump.
  • 8. A system comprising: a pump configured to deliver insulin;an input configured to receive sensor glucose data representative of a blood glucose level of a user from a continuous glucose monitor via a wireless connection; anda controller communicatively coupled to the pump and the input, the controller configured to: monitor the sensor glucose data from the continuous glucose monitor;determine a rate of change of the blood glucose level of the user and a current glucose level from the sensor glucose data;compare the current glucose level of the user and the rate of change of the blood glucose level to a target glucose level;determine that a current insulin delivery pattern should be modified based on the current glucose level of the user and the rate of change of the blood glucose level;automatically calculate a modification to the insulin delivery pattern; andcause the pump to employ the modified insulin delivery pattern.
  • 9. The system of claim 8, wherein the target glucose level is a predetermined high glucose level, and the controller is configured to determine that the current insulin delivery pattern should be modified when the current glucose level of the user is not over the predetermined high glucose level but the rate of change indicates that there is a risk of the user going over the predetermined high glucose level in the future.
  • 10. The system of claim 9, wherein when the controller determines that the current insulin delivery pattern should be modified, the controller is configured to calculate the modification to the insulin delivery pattern by calculating an insulin correction bolus.
  • 11. The system of claim 8, wherein the target glucose level is a predetermined low glucose level, and the controller is configured to determine that the current insulin delivery pattern should be modified when the current glucose level of the user is not below the predetermined low glucose level but the rate of change indicates that there is a risk of the user going below the predetermined low glucose level in the future.
  • 12. The system of claim 11, wherein when the controller determines that the current insulin delivery pattern should be modified, the controller is configured to calculate the modification to the insulin delivery pattern by reducing an amount of insulin delivered.
  • 13. The system of claim 8, wherein the controller comparing the current glucose level to a target glucose level includes comparing the current glucose level to a target range of glucose levels.
  • 14. The system of claim 8, wherein the controller is configured to automatically deliver the modified insulin delivery pattern.
  • 15. The system of claim 8, wherein the controller is further configured to present a recommendation to modify the insulin delivery pattern on a user interface and to deliver the modified insulin delivery pattern only after receiving a confirmation in response to the recommendation.
  • 16. The system of claim 8, wherein the controller is further configured to provide a notification to the user regarding the modification to the insulin delivery pattern.
  • 17. The system of claim 8, wherein the controller, the input and the pump are part of a common device.
  • 18. The system of claim 8, wherein the controller and the input are part of a handheld device that is separate from the pump.
RELATED APPLICATIONS

This application is a continuation of application Ser. No. 15/830,415 filed Dec. 4, 2017, which in turn is a continuation of application Ser. No. 14/187,414 filed Feb. 24, 2014, now U.S. Pat. No. 9,833,177 issued Dec. 5, 2017, which in turn application is a continuation of application Ser. No. 13/465,570 filed May 7, 2012, now U.S. Pat. No. 8,657,779 issued Feb. 25, 2014, which in turn is a division of application Ser. No. 11/755,480 filed May 30, 2007, now U.S. Pat. No. 8,221,345 issued Jul. 17, 2012, each of which is hereby fully incorporated herein by reference.

US Referenced Citations (989)
Number Name Date Kind
2462596 Bent Feb 1949 A
2629376 Pierre Feb 1953 A
2691542 Chenoweth Oct 1954 A
3059639 Blackman et al. Oct 1962 A
4392849 Petre et al. Jul 1983 A
4393365 Kondo et al. Jul 1983 A
4403984 Ash et al. Sep 1983 A
4475901 Kraegen et al. Oct 1984 A
4538616 Rogoff Sep 1985 A
5000664 Lawless et al. Mar 1991 A
5050612 Matsumura Sep 1991 A
5122362 Phillips et al. Jun 1992 A
5153827 Coutre et al. Oct 1992 A
5181910 Scanlon Jan 1993 A
5207666 Idriss et al. May 1993 A
5219330 Bollish et al. Jun 1993 A
5311175 Waldman May 1994 A
5338157 Blomquist Aug 1994 A
5362562 Evans et al. Nov 1994 A
5364346 Schrezenmeir Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5376070 Purvis et al. Dec 1994 A
5389078 Zalesky et al. Feb 1995 A
5395326 Haber et al. Mar 1995 A
5482446 Williamson et al. Jan 1996 A
5485408 Blomquist Jan 1996 A
5497772 Schulman et al. Mar 1996 A
5536249 Castellano et al. Jul 1996 A
5551850 Williamson et al. Sep 1996 A
5558638 Evers et al. Sep 1996 A
5569186 Lord et al. Oct 1996 A
5658250 Blomquist et al. Aug 1997 A
5658252 Johnson Aug 1997 A
5660163 Schulman et al. Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5674240 Bonutti et al. Oct 1997 A
5681285 Ford et al. Oct 1997 A
5685844 Marttila Nov 1997 A
5695473 Olsen Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5745378 Barker et al. Apr 1998 A
5782805 Meinzer et al. Jul 1998 A
5810771 Blomquist Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822715 Worthington et al. Oct 1998 A
5876370 Blomquist Mar 1999 A
5879143 Cote et al. Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5919216 Houben et al. Jul 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5960403 Brown Sep 1999 A
6023629 Tamada Feb 2000 A
6024539 Blomquist Feb 2000 A
6077055 Vilks Jun 2000 A
6122536 Sun et al. Sep 2000 A
6142939 Eppstein et al. Nov 2000 A
6175752 Say et al. Jan 2001 B1
6232130 Wolf May 2001 B1
6233471 Berner et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248057 Mavity et al. Jun 2001 B1
6248065 Brown Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6249717 Nicholson et al. Jun 2001 B1
6255781 Tsumura Jul 2001 B1
6272364 Kurnik Aug 2001 B1
6298254 Tamada Oct 2001 B2
6306420 Cheikh Oct 2001 B1
6368272 Porumbescu Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6422057 Anderson Jul 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6475180 Peterson et al. Nov 2002 B2
6475750 Han et al. Nov 2002 B1
6505059 Kollias et al. Jan 2003 B1
6517482 Elden et al. Feb 2003 B1
6535714 Melker et al. Mar 2003 B2
6539250 Bettinger Mar 2003 B1
6544212 Galley et al. Apr 2003 B2
6544229 Danby et al. Apr 2003 B1
6546269 Kurnik Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6553244 Lesho et al. Apr 2003 B2
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6565509 Say et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6582366 Porumbescu Jun 2003 B1
6595919 Berner et al. Jul 2003 B2
6623698 Kuo Sep 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6641533 Causey, III et al. Nov 2003 B2
6648821 Lebel et al. Nov 2003 B2
6650951 Jones et al. Nov 2003 B1
6656114 Poulsen et al. Dec 2003 B1
6659978 Kasuga et al. Dec 2003 B1
6668196 Villegas et al. Dec 2003 B1
6687522 Tamada Feb 2004 B2
6692456 Eppstein et al. Feb 2004 B1
6694191 Starkweather et al. Feb 2004 B2
6740072 Starkweather et al. May 2004 B2
6740075 Lebel et al. May 2004 B2
6744350 Blomquist Jun 2004 B2
6771250 Oh Aug 2004 B1
6773412 O'Mahony et al. Aug 2004 B2
6790198 White et al. Sep 2004 B1
6809563 Schaal Oct 2004 B2
6809653 Mann et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6827702 Lebel et al. Dec 2004 B2
6835175 Porumbescu Dec 2004 B1
6852104 Blomquist Feb 2005 B2
6862466 Ackerman Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6880564 Erickson Apr 2005 B2
6882940 Potts et al. Apr 2005 B2
6895263 Shin et al. May 2005 B2
6902905 Burson et al. Jun 2005 B2
6916159 Rush et al. Jul 2005 B2
6918542 Silverbrook et al. Jul 2005 B2
6934220 Cruitt et al. Aug 2005 B1
6936029 Mann et al. Aug 2005 B2
6957655 Erickson et al. Oct 2005 B2
6958705 Lebel et al. Oct 2005 B2
6966325 Erickson Nov 2005 B2
6970742 Mann et al. Nov 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6997920 Mann et al. Feb 2006 B2
6998387 Goke et al. Feb 2006 B1
6999854 Roth Feb 2006 B2
7004928 Aceti et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7022072 Fox et al. Apr 2006 B2
7024236 Ford et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7033338 Vilks et al. Apr 2006 B2
7041082 Blomquist et al. May 2006 B2
7073713 Silverbrook et al. Jul 2006 B2
7083108 Silverbrook et al. Aug 2006 B2
7092011 Silverbrook et al. Aug 2006 B2
7097104 Silverbrook et al. Aug 2006 B2
7097108 Zellner et al. Aug 2006 B2
7098803 Mann et al. Aug 2006 B2
7109878 Mann et al. Sep 2006 B2
7150741 Erickson et al. Dec 2006 B2
7156808 Quy Jan 2007 B2
7179226 Crothall et al. Feb 2007 B2
7181505 Haller et al. Feb 2007 B2
7183068 Burson et al. Feb 2007 B2
7187404 Silverbrook et al. Mar 2007 B2
7201319 Silverbrook et al. Apr 2007 B2
7204823 Estes et al. Apr 2007 B2
7231263 Choi Jun 2007 B2
7234645 Silverbrook et al. Jun 2007 B2
7247702 Gardner et al. Jul 2007 B2
7251516 Walker et al. Jul 2007 B2
7254782 Sherer Aug 2007 B1
7267665 Steil et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7282029 Poulsen et al. Oct 2007 B1
7289142 Silverbrook Oct 2007 B2
7291107 Hellwig et al. Nov 2007 B2
7295867 Berner et al. Nov 2007 B2
7307245 Faries, Jr. et al. Dec 2007 B2
7320675 Pastore et al. Jan 2008 B2
7324012 Mann et al. Jan 2008 B2
7341577 Gill Mar 2008 B2
7347836 Peterson et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7362971 Silverbrook et al. Apr 2008 B2
7373083 Silverbrook et al. May 2008 B2
7377706 Silverbrook et al. May 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7404796 Ginsberg Jul 2008 B2
7440806 Whitehurst et al. Oct 2008 B1
7446091 Van Den Berghe Nov 2008 B2
7460152 Silverbrook et al. Dec 2008 B2
7464010 Yang et al. Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7475825 Silverbrook et al. Jan 2009 B2
7483050 Silverbrook et al. Jan 2009 B2
7483743 Mann et al. Jan 2009 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7515060 Blomquist Apr 2009 B2
7524045 Silverbrook et al. Apr 2009 B2
7534226 Mernoe et al. May 2009 B2
7547281 Hayes et al. Jun 2009 B2
7553281 Hellwig et al. Jun 2009 B2
7556613 Wittmann et al. Jul 2009 B2
7559926 Blischak Jul 2009 B1
7569030 Lebel et al. Aug 2009 B2
7572789 Cowen et al. Aug 2009 B2
7588046 Erickson Sep 2009 B1
7591801 Brauker et al. Sep 2009 B2
7602310 Mann et al. Oct 2009 B2
7604593 Parris et al. Oct 2009 B2
7615007 Shults et al. Nov 2009 B2
7647237 Malave et al. Jan 2010 B2
7651489 Estes et al. Jan 2010 B2
7651845 Doyle, III et al. Jan 2010 B2
7654976 Peterson et al. Feb 2010 B2
7674485 Bhaskaran et al. Mar 2010 B2
7676519 McBride et al. Mar 2010 B2
7678071 Lebel et al. Mar 2010 B2
7678762 Green et al. Mar 2010 B2
7678763 Green et al. Mar 2010 B2
7687272 Buchwald et al. Mar 2010 B1
7697967 Stafford Apr 2010 B2
7699775 Desai et al. Apr 2010 B2
7704226 Mueller, Jr. et al. Apr 2010 B2
7708717 Estes et al. May 2010 B2
7711402 Shults et al. May 2010 B2
7713574 Brister et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
7717903 Estes et al. May 2010 B2
7722536 Goodnow May 2010 B2
7734323 Blomquist et al. Jun 2010 B2
7751907 Blomquist Jul 2010 B2
7766829 Sloan et al. Aug 2010 B2
7766830 Fox et al. Aug 2010 B2
7768386 Hayter et al. Aug 2010 B2
7768408 Reggiardo et al. Aug 2010 B2
7774145 Brauker et al. Aug 2010 B2
7775975 Brister et al. Aug 2010 B2
7776030 Estes et al. Aug 2010 B2
7778680 Goode, Jr. et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7794426 Briones et al. Sep 2010 B2
7794427 Estes et al. Sep 2010 B2
7794428 Estes et al. Sep 2010 B2
7797028 Goode, Jr. et al. Sep 2010 B2
7801582 Peyser Sep 2010 B2
7806853 Wittmann et al. Oct 2010 B2
7806854 Damiano et al. Oct 2010 B2
7806886 Kanderian, Jr. et al. Oct 2010 B2
7811231 Jin et al. Oct 2010 B2
7815602 Mann et al. Oct 2010 B2
7819843 Mann et al. Oct 2010 B2
7822455 Hoss et al. Oct 2010 B2
7826879 Hoss et al. Nov 2010 B2
7828528 Estes et al. Nov 2010 B2
7831310 Lebel et al. Nov 2010 B2
7833196 Estes et al. Nov 2010 B2
7837647 Estes et al. Nov 2010 B2
7837651 Bishop et al. Nov 2010 B2
7850641 Lebel et al. Dec 2010 B2
7860544 Say et al. Dec 2010 B2
7869851 Hellwig et al. Jan 2011 B2
7869853 Say et al. Jan 2011 B1
7875022 Wenger et al. Jan 2011 B2
7884729 Reggiardo et al. Feb 2011 B2
7885699 Say et al. Feb 2011 B2
7887512 Estes et al. Feb 2011 B2
7890295 Shin et al. Feb 2011 B2
7892199 Mhatre et al. Feb 2011 B2
7901394 Ireland et al. Mar 2011 B2
7912674 Killoren Clark et al. Mar 2011 B2
7914450 Goode et al. Mar 2011 B2
7914499 Gonnelli et al. Mar 2011 B2
7920907 McGarraugh et al. Apr 2011 B2
7933780 De La Huerga Apr 2011 B2
7935076 Estes et al. May 2011 B2
7938797 Estes May 2011 B2
7938803 Mernoe et al. May 2011 B2
7941200 Weinert et al. May 2011 B2
7942844 Moberg et al. May 2011 B2
7946985 Mastrototaro et al. May 2011 B2
7951114 Rush et al. May 2011 B2
7959598 Estes Jun 2011 B2
7963946 Moubayed et al. Jun 2011 B2
7967773 Amborn et al. Jun 2011 B2
7972296 Braig et al. Jul 2011 B2
7976492 Brauker et al. Jul 2011 B2
7981034 Jennewine et al. Jul 2011 B2
7981084 Estes et al. Jul 2011 B2
7981102 Patel et al. Jul 2011 B2
7983745 Hatlestad et al. Jul 2011 B2
7983759 Stahmann et al. Jul 2011 B2
7985330 Wang et al. Jul 2011 B2
7988630 Osorio et al. Aug 2011 B1
7988849 Biewer et al. Aug 2011 B2
7996158 Hayter et al. Aug 2011 B2
8000763 Mazza et al. Aug 2011 B2
8005524 Brauker et al. Aug 2011 B2
8012119 Estes et al. Sep 2011 B2
8016783 Pastore et al. Sep 2011 B2
8025634 Moubayed et al. Sep 2011 B1
8029443 Goodnow Oct 2011 B2
8029459 Rush et al. Oct 2011 B2
8029460 Rush et al. Oct 2011 B2
8062249 Wilinska et al. Nov 2011 B2
8066665 Rush et al. Nov 2011 B2
8075527 Rush et al. Dec 2011 B2
8079983 Rush et al. Dec 2011 B2
8079984 Rush et al. Dec 2011 B2
8083718 Rush et al. Dec 2011 B2
8088098 Yodfat et al. Jan 2012 B2
8090435 Gill et al. Jan 2012 B2
8093212 Gardner et al. Jan 2012 B2
8105268 Lebel et al. Jan 2012 B2
8105279 Mernoe et al. Jan 2012 B2
8109921 Estes et al. Feb 2012 B2
8114350 Silver et al. Feb 2012 B1
8118770 Galley et al. Feb 2012 B2
8119593 Richardson et al. Feb 2012 B2
8121857 Galasso et al. Feb 2012 B2
8127046 Grant et al. Feb 2012 B2
8129429 Sporn et al. Mar 2012 B2
8133197 Blomquist et al. Mar 2012 B2
8140275 Campbell et al. Mar 2012 B2
8140312 Hayter et al. Mar 2012 B2
RE43316 Brown et al. Apr 2012 E
8147446 Yodfat et al. Apr 2012 B2
8152789 Starkweather et al. Apr 2012 B2
8170721 Nickerson May 2012 B2
8177716 Say et al. May 2012 B2
8182445 Moubayed et al. May 2012 B2
8187183 Jin et al. May 2012 B2
8192394 Estes et al. Jun 2012 B2
8192395 Estes et al. Jun 2012 B2
8202267 Field et al. Jun 2012 B2
8204729 Sher Jun 2012 B2
8206296 Jennewine Jun 2012 B2
8206350 Mann et al. Jun 2012 B2
8208984 Blomquist et al. Jun 2012 B2
8211062 Estes et al. Jul 2012 B2
8219222 Blomquist Jul 2012 B2
8221345 Blomquist Jul 2012 B2
8221385 Estes Jul 2012 B2
8226558 Say et al. Jul 2012 B2
8226891 Sloan et al. Jul 2012 B2
8231562 Buck et al. Jul 2012 B2
8234126 Estes Jul 2012 B1
8234128 Martucci et al. Jul 2012 B2
8237715 Buck et al. Aug 2012 B2
8246540 Ginsberg Aug 2012 B2
8250483 Blomquist Aug 2012 B2
8251904 Zivitz et al. Aug 2012 B2
8251906 Brauker et al. Aug 2012 B2
8257259 Brauker et al. Sep 2012 B2
8257300 Budiman et al. Sep 2012 B2
8260630 Brown Sep 2012 B2
8262617 Aeschlimann et al. Sep 2012 B2
8275438 Simpson et al. Sep 2012 B2
8277435 Estes Oct 2012 B2
8282601 Mernoe et al. Oct 2012 B2
8287454 Wolpert et al. Oct 2012 B2
8287487 Estes Oct 2012 B2
8287495 Michaud et al. Oct 2012 B2
8287514 Miller et al. Oct 2012 B2
8290562 Goode, Jr. et al. Oct 2012 B2
8298184 Diperna et al. Oct 2012 B2
8308680 Chawla Nov 2012 B1
8311749 Brauker et al. Nov 2012 B2
8323188 Tran Dec 2012 B2
8326546 Stewart et al. Dec 2012 B2
8328754 Estes et al. Dec 2012 B2
8343092 Rush et al. Jan 2013 B2
8344847 Moberg et al. Jan 2013 B2
8346399 Blomquist Jan 2013 B2
8348885 Moberg et al. Jan 2013 B2
8348886 Kanderian et al. Jan 2013 B2
8348923 Kanderian et al. Jan 2013 B2
8349319 Schuchman et al. Jan 2013 B2
8353881 Jennewine Jan 2013 B2
8357091 Say et al. Jan 2013 B2
8369919 Kamath et al. Feb 2013 B2
8372040 Huang et al. Feb 2013 B2
8376943 Kovach et al. Feb 2013 B2
8377031 Hayter et al. Feb 2013 B2
8380273 Say et al. Feb 2013 B2
8409131 Say et al. Apr 2013 B2
8414523 Blomquist et al. Apr 2013 B2
8414532 Brandt et al. Apr 2013 B2
8444595 Brukalo et al. May 2013 B2
8449523 Brukalo et al. May 2013 B2
8449524 Braig et al. May 2013 B2
8451230 Celentano et al. May 2013 B2
8452953 Buck et al. May 2013 B2
8454510 Yodfat et al. Jun 2013 B2
8454575 Estes et al. Jun 2013 B2
8454576 Mastrototaro et al. Jun 2013 B2
8454581 Estes et al. Jun 2013 B2
8460231 Brauker et al. Jun 2013 B2
8465460 Yodfat et al. Jun 2013 B2
8467980 Campbell et al. Jun 2013 B2
8486005 Yodfat et al. Jul 2013 B2
8552880 Kopp et al. Oct 2013 B2
8562558 Kamath et al. Oct 2013 B2
8573027 Rosinko et al. Nov 2013 B2
8579853 Reggiardo et al. Nov 2013 B2
8650937 Brown Feb 2014 B2
8657779 Blomquist Feb 2014 B2
8706691 McDaniel et al. Apr 2014 B2
8712748 Thukral et al. Apr 2014 B2
8718949 Blomquist et al. May 2014 B2
8726266 Kiaie et al. May 2014 B2
8775877 Mcvey et al. Jul 2014 B2
8801657 Blomquist et al. Aug 2014 B2
8852152 Tverskoy Oct 2014 B2
8882701 Debelser et al. Nov 2014 B2
8926561 Verhoef Jan 2015 B2
8932250 Montgomery Jan 2015 B2
8936565 Chawla Jan 2015 B2
8961465 Blomquist Feb 2015 B2
8985253 Winter et al. Mar 2015 B2
8986253 Diperna Mar 2015 B2
8992475 Mann Mar 2015 B2
9008803 Blomquist Apr 2015 B2
9037254 John May 2015 B2
9049982 Brukalo Jun 2015 B2
9089305 Hovorka Jul 2015 B2
9114210 Estes Aug 2015 B2
9132227 Bryant, Jr. Sep 2015 B2
9364679 John Jun 2016 B2
9474856 Blomquist Oct 2016 B2
9483615 Roberts Nov 2016 B2
9486171 Saint Nov 2016 B2
9486578 Finan et al. Nov 2016 B2
9492608 Saint Nov 2016 B2
9669160 Harris et al. Jun 2017 B2
9833177 Blomquist Dec 2017 B2
9867937 Saint et al. Jan 2018 B2
9867953 Rosinko Jan 2018 B2
9968302 Fennell May 2018 B2
9968306 Cole May 2018 B2
9968729 Estes May 2018 B2
9974472 Hayter et al. May 2018 B2
9974903 Davis May 2018 B1
10016559 Debelser et al. Jul 2018 B2
10016561 Saint et al. Jul 2018 B2
10052049 Blomquist et al. Aug 2018 B2
10207047 Estes Feb 2019 B2
10213547 Rosinko Feb 2019 B2
10357606 Rosinko et al. Jul 2019 B2
10357607 Blomquist et al. Jul 2019 B2
20010001144 Kapp May 2001 A1
20010027791 Wallace et al. Oct 2001 A1
20010031944 Peterson et al. Oct 2001 A1
20010037217 Abensour et al. Nov 2001 A1
20010041831 Starkweather et al. Nov 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020016568 Lebel et al. Feb 2002 A1
20020065454 Lebel et al. May 2002 A1
20020072932 Swamy Jun 2002 A1
20020077852 Ford et al. Jun 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020183693 Peterson et al. Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20030028089 Galley et al. Feb 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030055323 Choi Mar 2003 A1
20030060765 Campbell et al. Mar 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030088238 Poulsen et al. May 2003 A1
20030104982 Wittmann et al. Jun 2003 A1
20030114836 Estes et al. Jun 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030145854 Hickle Aug 2003 A1
20030159945 Miyazaki et al. Aug 2003 A1
20030160683 Blomquist Aug 2003 A1
20030161744 Vilks et al. Aug 2003 A1
20030163088 Blomquist Aug 2003 A1
20030163090 Blomquist et al. Aug 2003 A1
20030163223 Blomquist Aug 2003 A1
20030163789 Blomquist Aug 2003 A1
20030199854 Kovach et al. Oct 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030211617 Jones Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030236489 Jacobson et al. Dec 2003 A1
20040015102 Cummings et al. Jan 2004 A1
20040015132 Brown Jan 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040068230 Estes et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040115067 Rush et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040167464 Ireland et al. Aug 2004 A1
20040180810 Pilarski Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040199409 Brown Oct 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040225252 Gillespie et al. Nov 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050017151 Battig Jan 2005 A1
20050019755 Marchessault et al. Jan 2005 A1
20050021006 Tonnies Jan 2005 A1
20050022274 Campbell et al. Jan 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050030164 Blomquist Feb 2005 A1
20050038332 Saidara Feb 2005 A1
20050049179 Davidson et al. Mar 2005 A1
20050050621 Thomas Mar 2005 A1
20050065464 Talbot et al. Mar 2005 A1
20050065760 Murtfeldt et al. Mar 2005 A1
20050081847 Lee et al. Apr 2005 A1
20050095063 Fathallah et al. May 2005 A1
20050137530 Campbell et al. Jun 2005 A1
20050143864 Blomquist Jun 2005 A1
20050159656 Hockersmith et al. Jul 2005 A1
20050171503 Van et al. Aug 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050182358 Veit et al. Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197553 Cooper Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050203349 Nanikashvili Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050228234 Yang Oct 2005 A1
20050272640 Doyle, III et al. Dec 2005 A1
20050277872 Colby, Jr. et al. Dec 2005 A1
20050277912 John Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060001550 Mann et al. Jan 2006 A1
20060009727 O'Mahony et al. Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060014670 Green et al. Jan 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060047192 Hellwig et al. Mar 2006 A1
20060047538 Condurso et al. Mar 2006 A1
20060060765 Huang Mar 2006 A1
20060080059 Stupp et al. Apr 2006 A1
20060085223 Anderson et al. Apr 2006 A1
20060093785 Hickle May 2006 A1
20060094985 Aceti et al. May 2006 A1
20060122577 Poulsen et al. Jun 2006 A1
20060132292 Blomquist Jun 2006 A1
20060137695 Hellwig et al. Jun 2006 A1
20060167345 Vespasiani Jul 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060202859 Mastrototaro et al. Sep 2006 A1
20060224109 Steil et al. Oct 2006 A1
20060253097 Braig et al. Nov 2006 A1
20060253296 Liisberg et al. Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060271020 Huang et al. Nov 2006 A1
20060272652 Stocker et al. Dec 2006 A1
20060276771 Galley et al. Dec 2006 A1
20070010950 Abensour et al. Jan 2007 A1
20070016127 Staib et al. Jan 2007 A1
20070016170 Kovelman Jan 2007 A1
20070016449 Cohen et al. Jan 2007 A1
20070021733 Hansen et al. Jan 2007 A1
20070033074 Nitzan et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060871 Istoc et al. Mar 2007 A1
20070060874 Nesbitt et al. Mar 2007 A1
20070066956 Finkel Mar 2007 A1
20070073236 Mernoe et al. Mar 2007 A1
20070078314 Grounsell et al. Apr 2007 A1
20070083152 Williams, Jr. et al. Apr 2007 A1
20070083335 Moerman Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100222 Mastrototaro et al. May 2007 A1
20070106135 Sloan et al. May 2007 A1
20070112261 Enegren et al. May 2007 A1
20070112298 Mueller, Jr. et al. May 2007 A1
20070112299 Smit et al. May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070124002 Estes et al. May 2007 A1
20070149861 Crothall et al. Jun 2007 A1
20070156033 Causey, III et al. Jul 2007 A1
20070156092 Estes et al. Jul 2007 A1
20070156457 Brown Jul 2007 A1
20070167905 Estes et al. Jul 2007 A1
20070167912 Causey et al. Jul 2007 A1
20070173712 Shah et al. Jul 2007 A1
20070173761 Kanderian, Jr. Jul 2007 A1
20070173762 Estes et al. Jul 2007 A1
20070179355 Rosen Aug 2007 A1
20070179444 Causey et al. Aug 2007 A1
20070203454 Shermer et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070233051 Hohl et al. Oct 2007 A1
20070245258 Ginggen et al. Oct 2007 A1
20070251835 Mehta et al. Nov 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070253380 Jollota et al. Nov 2007 A1
20070254593 Jollota et al. Nov 2007 A1
20070255116 Mehta et al. Nov 2007 A1
20070255125 Moberg et al. Nov 2007 A1
20070255126 Moberg et al. Nov 2007 A1
20070255250 Moberg et al. Nov 2007 A1
20070255348 Holtzclaw Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070287985 Estes et al. Dec 2007 A1
20070299389 Halbert et al. Dec 2007 A1
20080004601 Jennewine et al. Jan 2008 A1
20080017203 Fagg et al. Jan 2008 A1
20080030369 Mann et al. Feb 2008 A1
20080033357 Mann et al. Feb 2008 A1
20080033360 Evans et al. Feb 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080045902 Estes et al. Feb 2008 A1
20080045903 Estes et al. Feb 2008 A1
20080045904 Estes et al. Feb 2008 A1
20080045931 Estes et al. Feb 2008 A1
20080051709 Mounce et al. Feb 2008 A1
20080051714 Moberg et al. Feb 2008 A1
20080051716 Stutz Feb 2008 A1
20080058773 John Mar 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065016 Peterson et al. Mar 2008 A1
20080071209 Moubayed et al. Mar 2008 A1
20080071210 Moubayed et al. Mar 2008 A1
20080071217 Moubayed et al. Mar 2008 A1
20080071251 Moubayed et al. Mar 2008 A1
20080071580 Marcus et al. Mar 2008 A1
20080076969 Kraft et al. Mar 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080103447 Reggiardo et al. May 2008 A1
20080106431 Blomquist May 2008 A1
20080114299 Damgaard-Sorensen et al. May 2008 A1
20080132844 Peterson et al. Jun 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080139910 Mastrototaro et al. Jun 2008 A1
20080147004 Mann et al. Jun 2008 A1
20080147041 Kristensen Jun 2008 A1
20080147042 Pettis et al. Jun 2008 A1
20080147050 Mann et al. Jun 2008 A1
20080154513 Kovatchev et al. Jun 2008 A1
20080156661 Cooper et al. Jul 2008 A1
20080171697 Jacotot et al. Jul 2008 A1
20080171967 Blomquist et al. Jul 2008 A1
20080172026 Blomquist Jul 2008 A1
20080172027 Blomquist Jul 2008 A1
20080172028 Blomquist Jul 2008 A1
20080172029 Blomquist Jul 2008 A1
20080172030 Blomquist Jul 2008 A1
20080172031 Blomquist Jul 2008 A1
20080177165 Blomquist et al. Jul 2008 A1
20080183060 Steil et al. Jul 2008 A1
20080206799 Blomquist Aug 2008 A1
20080222246 Ebling et al. Sep 2008 A1
20080228055 Sher Sep 2008 A1
20080228056 Blomquist et al. Sep 2008 A1
20080249470 Malave et al. Oct 2008 A1
20080255438 Saidara et al. Oct 2008 A1
20080255517 Nair et al. Oct 2008 A1
20080264024 Baaken Oct 2008 A1
20080269585 Ginsberg Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080287922 Panduro Nov 2008 A1
20080288115 Rusnak et al. Nov 2008 A1
20080294024 Cosentino et al. Nov 2008 A1
20080294094 Mhatre et al. Nov 2008 A1
20080294108 Briones et al. Nov 2008 A1
20080294109 Estes et al. Nov 2008 A1
20080294142 Patel et al. Nov 2008 A1
20080294294 Blomquist Nov 2008 A1
20080300534 Blomquist Dec 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080300651 Gerber et al. Dec 2008 A1
20080306353 Douglas et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080312584 Montgomery et al. Dec 2008 A1
20080312585 Brukalo et al. Dec 2008 A1
20090005726 Jones et al. Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090006129 Thukral et al. Jan 2009 A1
20090018779 Cohen et al. Jan 2009 A1
20090030733 Cohen et al. Jan 2009 A1
20090036753 King Feb 2009 A1
20090054475 Chen et al. Feb 2009 A1
20090054750 Jennewine Feb 2009 A1
20090067989 Estes et al. Mar 2009 A1
20090069745 Estes et al. Mar 2009 A1
20090069749 Miller et al. Mar 2009 A1
20090069787 Estes et al. Mar 2009 A1
20090085768 Patel et al. Apr 2009 A1
20090088731 Campbell et al. Apr 2009 A1
20090093756 Minaie et al. Apr 2009 A1
20090105636 Hayter et al. Apr 2009 A1
20090105646 Hendrixson et al. Apr 2009 A1
20090112626 Talbot et al. Apr 2009 A1
20090118592 Klitgaard May 2009 A1
20090131860 Nielsen May 2009 A1
20090131861 Braig et al. May 2009 A1
20090143661 Taub et al. Jun 2009 A1
20090150186 Cohen et al. Jun 2009 A1
20090150865 Young et al. Jun 2009 A1
20090156990 Wenger et al. Jun 2009 A1
20090157003 Jones et al. Jun 2009 A1
20090163855 Shin et al. Jun 2009 A1
20090164239 Hayter et al. Jun 2009 A1
20090171269 Jennewine et al. Jul 2009 A1
20090177142 Blomquist et al. Jul 2009 A1
20090177147 Blomquist et al. Jul 2009 A1
20090177154 Blomquist Jul 2009 A1
20090177180 Rubalcaba, Jr. et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090212966 Panduro Aug 2009 A1
20090216100 Ebner et al. Aug 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090247931 Damgaard-Sorensen Oct 2009 A1
20090247982 Krulevitch et al. Oct 2009 A1
20090254037 Bryant, Jr. et al. Oct 2009 A1
20090267774 Enegren et al. Oct 2009 A1
20090267775 Enegren et al. Oct 2009 A1
20090270705 Enegren et al. Oct 2009 A1
20090270810 Debelser et al. Oct 2009 A1
20090275886 Blomquist et al. Nov 2009 A1
20090275887 Estes Nov 2009 A1
20090281393 Smith Nov 2009 A1
20100008795 Diperna Jan 2010 A1
20100010330 Rankers et al. Jan 2010 A1
20100030045 Gottlieb et al. Feb 2010 A1
20100030387 Sen Feb 2010 A1
20100049164 Estes Feb 2010 A1
20100056993 Chase Mar 2010 A1
20100057040 Hayter Mar 2010 A1
20100057043 Kovatchev et al. Mar 2010 A1
20100064257 Buck et al. Mar 2010 A1
20100069730 Bergstrom et al. Mar 2010 A1
20100081993 O'Connor Apr 2010 A1
20100094110 Heller et al. Apr 2010 A1
20100094251 Estes Apr 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100105999 Dixon et al. Apr 2010 A1
20100114015 Kanderian, Jr. et al. May 2010 A1
20100121169 Petisce et al. May 2010 A1
20100121170 Rule May 2010 A1
20100125241 Prud et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100138197 Sher Jun 2010 A1
20100145173 Alferness et al. Jun 2010 A1
20100145276 Yodfat et al. Jun 2010 A1
20100145303 Yodfat et al. Jun 2010 A1
20100156633 Buck, Jr. et al. Jun 2010 A1
20100160740 Cohen et al. Jun 2010 A1
20100161236 Cohen et al. Jun 2010 A1
20100161346 Getschmann et al. Jun 2010 A1
20100162786 Keenan et al. Jul 2010 A1
20100168538 Keenan et al. Jul 2010 A1
20100174266 Estes Jul 2010 A1
20100174553 Kaufman et al. Jul 2010 A1
20100179402 Goode, Jr. et al. Jul 2010 A1
20100185142 Kamen et al. Jul 2010 A1
20100185152 Larsen et al. Jul 2010 A1
20100185175 Kamen et al. Jul 2010 A1
20100192686 Kamen et al. Aug 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198142 Sloan et al. Aug 2010 A1
20100202040 Morgan Aug 2010 A1
20100205001 Knudsen et al. Aug 2010 A1
20100218132 Soni et al. Aug 2010 A1
20100222765 Blomquist et al. Sep 2010 A1
20100228186 Estes et al. Sep 2010 A1
20100234709 Say et al. Sep 2010 A1
20100235439 Goodnow Sep 2010 A1
20100249530 Rankers et al. Sep 2010 A1
20100249561 Patek et al. Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100262078 Blomquist Oct 2010 A1
20100262117 Magni et al. Oct 2010 A1
20100262434 Shaya Oct 2010 A1
20100274218 Yodfat et al. Oct 2010 A1
20100274592 Nitzan et al. Oct 2010 A1
20100274751 Blomquist Oct 2010 A1
20100277119 Montague et al. Nov 2010 A1
20100280329 Randloev et al. Nov 2010 A1
20100280442 Shahmirian et al. Nov 2010 A1
20100286563 Bryer et al. Nov 2010 A1
20100286601 Yodfat et al. Nov 2010 A1
20100286653 Kubel et al. Nov 2010 A1
20100292634 Kircher, Jr. Nov 2010 A1
20100295686 Sloan et al. Nov 2010 A1
20100298681 Say et al. Nov 2010 A1
20100298685 Hayter et al. Nov 2010 A1
20100305421 Ow-Wing Dec 2010 A1
20100305545 Kanderian, Jr. et al. Dec 2010 A1
20100305965 Benjamin et al. Dec 2010 A1
20100312085 Andrews et al. Dec 2010 A1
20100317950 Galley et al. Dec 2010 A1
20100317951 Rutkowski et al. Dec 2010 A1
20100324382 Cantwell et al. Dec 2010 A1
20100324398 Tzyy-Ping Dec 2010 A1
20100324932 Galley et al. Dec 2010 A1
20100331651 Groll Dec 2010 A1
20110004188 Shekalim Jan 2011 A1
20110006876 Moberg et al. Jan 2011 A1
20110009725 Hill et al. Jan 2011 A1
20110009813 Rankers Jan 2011 A1
20110010105 Shah et al. Jan 2011 A1
20110015509 Peyser Jan 2011 A1
20110021898 Wei et al. Jan 2011 A1
20110022025 Savoie et al. Jan 2011 A1
20110033833 Blomquist et al. Feb 2011 A1
20110034792 Williams et al. Feb 2011 A1
20110040247 Mandro et al. Feb 2011 A1
20110040251 Blomquist et al. Feb 2011 A1
20110046051 Moerman Feb 2011 A1
20110046892 Moerman Feb 2011 A1
20110047499 Mandro et al. Feb 2011 A1
20110048938 Shah et al. Mar 2011 A1
20110048941 Shah et al. Mar 2011 A1
20110050428 Istoc Mar 2011 A1
20110053121 Heaton Mar 2011 A1
20110054281 Shah et al. Mar 2011 A1
20110054390 Searle et al. Mar 2011 A1
20110054391 Ward et al. Mar 2011 A1
20110056264 Kaplan et al. Mar 2011 A1
20110058485 Sloan Mar 2011 A1
20110060281 Aeschlimann et al. Mar 2011 A1
20110071372 Sloan et al. Mar 2011 A1
20110071464 Palerm Mar 2011 A1
20110071465 Wang et al. Mar 2011 A1
20110071765 Yodfat et al. Mar 2011 A1
20110077481 Say et al. Mar 2011 A1
20110077493 Shadforth et al. Mar 2011 A1
20110077963 Knudsen et al. Mar 2011 A1
20110082439 Wenger et al. Apr 2011 A1
20110087165 Amborn et al. Apr 2011 A1
20110092788 Long et al. Apr 2011 A1
20110092894 McGill et al. Apr 2011 A1
20110098548 Budiman et al. Apr 2011 A1
20110098637 Hill Apr 2011 A1
20110098638 Chawla et al. Apr 2011 A1
20110098674 Vicente et al. Apr 2011 A1
20110101995 Shah et al. May 2011 A1
20110105873 Feldman et al. May 2011 A1
20110105955 Yudovsky et al. May 2011 A1
20110106011 Cinar et al. May 2011 A1
20110106049 Damiano et al. May 2011 A1
20110106050 Yodfat et al. May 2011 A1
20110106480 Shah et al. May 2011 A1
20110112504 Causey et al. May 2011 A1
20110112505 Starkweather et al. May 2011 A1
20110112506 Starkweather et al. May 2011 A1
20110118578 Timmerman May 2011 A1
20110118662 Mhatre et al. May 2011 A1
20110118699 Yodfat et al. May 2011 A1
20110124996 Reinke et al. May 2011 A1
20110124999 Reggiardo et al. May 2011 A1
20110125085 Mcgill et al. May 2011 A1
20110125095 Lebel et al. May 2011 A1
20110126188 Bernstein et al. May 2011 A1
20110130716 Estes et al. Jun 2011 A1
20110130746 Budiman Jun 2011 A1
20110133946 Kopp et al. Jun 2011 A1
20110137239 Debelser et al. Jun 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110144616 Michaud et al. Jun 2011 A1
20110152770 Diperna et al. Jun 2011 A1
20110152824 Diperna et al. Jun 2011 A1
20110160654 Hanson et al. Jun 2011 A1
20110160695 Sigrist et al. Jun 2011 A1
20110163881 Halff et al. Jul 2011 A1
20110166544 Verhoef et al. Jul 2011 A1
20110166875 Hayter et al. Jul 2011 A1
20110172744 Davis et al. Jul 2011 A1
20110178461 Chong et al. Jul 2011 A1
20110178462 Moberg et al. Jul 2011 A1
20110178717 Goodnow et al. Jul 2011 A1
20110184264 Galasso et al. Jul 2011 A1
20110184342 Pesach et al. Jul 2011 A1
20110190614 Brister et al. Aug 2011 A1
20110190701 Remde et al. Aug 2011 A1
20110193704 Harper et al. Aug 2011 A1
20110196213 Thukral et al. Aug 2011 A1
20110202040 Remde et al. Aug 2011 A1
20110205065 Strachan et al. Aug 2011 A1
20110208155 Palerm et al. Aug 2011 A1
20110213225 Bernstein et al. Sep 2011 A1
20110213306 Hanson et al. Sep 2011 A1
20110238033 Prod'hom et al. Sep 2011 A1
20110256024 Cole et al. Oct 2011 A1
20110257625 Jasperson et al. Oct 2011 A1
20110257627 Hovorka Oct 2011 A1
20110257895 Brauker et al. Oct 2011 A1
20110266999 Yodfat et al. Nov 2011 A1
20120013625 Blomquist et al. Jan 2012 A1
20120013802 Blomquist et al. Jan 2012 A1
20120029433 Michaud et al. Feb 2012 A1
20120029468 Diperna Feb 2012 A1
20120029941 Malave et al. Feb 2012 A1
20120030610 Diperna et al. Feb 2012 A1
20120041415 Estes et al. Feb 2012 A1
20120053522 Yodfat et al. Mar 2012 A1
20120059353 Kovatchev et al. Mar 2012 A1
20120059673 Cohen et al. Mar 2012 A1
20120095315 Tenbarge et al. Apr 2012 A1
20120109100 Estes et al. May 2012 A1
20120123230 Brown et al. May 2012 A1
20120163481 Ebner et al. Jun 2012 A1
20120185267 Kamen et al. Jul 2012 A1
20120191061 Yodfat et al. Jul 2012 A1
20120191063 Brauker et al. Jul 2012 A1
20120203178 Tverskoy Aug 2012 A1
20120226124 Blomquist Sep 2012 A1
20120232484 Blomquist Sep 2012 A1
20120232485 Blomquist Sep 2012 A1
20120232520 Sloan et al. Sep 2012 A1
20120232521 Blomquist Sep 2012 A1
20120238852 Brauker et al. Sep 2012 A1
20120238854 Blomquist et al. Sep 2012 A1
20120239362 Blomquist Sep 2012 A1
20120245524 Estes et al. Sep 2012 A1
20120265722 Blomquist Oct 2012 A1
20120296269 Blomquist Nov 2012 A1
20120302991 Blomquist et al. Nov 2012 A1
20120330227 Budiman et al. Dec 2012 A1
20130012917 Miller et al. Jan 2013 A1
20130046281 Javitt Feb 2013 A1
20130053816 Diperna et al. Feb 2013 A1
20130116649 Breton May 2013 A1
20130131630 Blomquist May 2013 A1
20130324824 Kamath et al. Dec 2013 A1
20130324928 Kruse Dec 2013 A1
20130331790 Brown et al. Dec 2013 A1
20130345625 Causey, III et al. Dec 2013 A1
20130345663 Agrawal et al. Dec 2013 A1
20140005633 Finan Jan 2014 A1
20140012511 Mensinger et al. Jan 2014 A1
20140019396 Carlsgaard et al. Jan 2014 A1
20140054883 Lanigan et al. Feb 2014 A1
20140066890 Sloan et al. Mar 2014 A1
20140074059 Howell et al. Mar 2014 A1
20140113553 Brukalo Apr 2014 A1
20140137641 Brown May 2014 A1
20140171772 Blomquist Jun 2014 A1
20140180203 Budiman Jun 2014 A1
20140200426 Taub Jul 2014 A1
20140273042 Saint Sep 2014 A1
20140275419 Ward et al. Sep 2014 A1
20140276419 Rosinko et al. Sep 2014 A1
20140276420 Rosinko Sep 2014 A1
20140276531 Walsh Sep 2014 A1
20140276553 Rosinko et al. Sep 2014 A1
20140276556 Saint et al. Sep 2014 A1
20140276570 Saint Sep 2014 A1
20140276574 Saint Sep 2014 A1
20140350371 Blomquist et al. Nov 2014 A1
20140374275 Morales et al. Dec 2014 A1
20140378898 Rosinko Dec 2014 A1
20150045770 Debelser et al. Feb 2015 A1
20150073337 Saint et al. Mar 2015 A1
20150119805 Blomquist Apr 2015 A1
20150157793 Kovelman Jun 2015 A1
20150174320 Grant et al. Jun 2015 A1
20150182693 Rosinko Jul 2015 A1
20150182695 Rosinko Jul 2015 A1
20150217044 Blomquist Aug 2015 A1
20150273147 Duke et al. Oct 2015 A1
20150314062 Blomquist et al. Nov 2015 A1
20150352282 Mazlish Dec 2015 A1
20160030669 Harris et al. Feb 2016 A1
20160082188 Blomquist et al. Mar 2016 A1
20160199571 Rosinko et al. Jul 2016 A1
20160228041 Heller et al. Aug 2016 A1
20170000943 Blomquist et al. Jan 2017 A1
20170043085 Rosinko Feb 2017 A1
20170182248 Rosinko Jun 2017 A1
20180092578 Blomquist Apr 2018 A1
20180093039 Estes Apr 2018 A1
20180110921 Saint et al. Apr 2018 A1
20180133397 Estes May 2018 A1
20180137252 Mairs et al. May 2018 A1
20180137938 Vaddiraju et al. May 2018 A1
20180161498 Estes Jun 2018 A1
20180193573 Rosinko Jul 2018 A1
20180304010 Debelser et al. Oct 2018 A1
20190022314 Schmidt Jan 2019 A1
20190175823 Rosinko Jun 2019 A1
20190328967 Blomquist Oct 2019 A1
Foreign Referenced Citations (55)
Number Date Country
399065 Jul 1924 DE
4407005 Mar 1995 DE
19819407 Nov 1999 DE
10121317 Nov 2002 DE
10352456 Jul 2005 DE
1102194 May 2001 EP
1571582 Sep 2005 EP
1500029 Apr 2007 EP
2006034323 Feb 2006 JP
2010503515 Feb 2010 JP
WO-0010628 Mar 2000 WO
WO-0045696 Aug 2000 WO
WO-0074753 Dec 2000 WO
WO-0152727 Jul 2001 WO
WO-02062212 Aug 2002 WO
WO-03082091 Oct 2003 WO
WO-2005046559 May 2005 WO
WO-2006061169 Jun 2006 WO
WO-2006127841 Nov 2006 WO
WO-2007000425 Jan 2007 WO
WO-2007056592 May 2007 WO
WO-2007089537 Aug 2007 WO
WO-2007149533 Dec 2007 WO
WO-2008036658 Mar 2008 WO
WO-2008048556 Apr 2008 WO
WO-2008048582 Apr 2008 WO
WO-2008048583 Apr 2008 WO
WO-2008048584 Apr 2008 WO
WO-2008048585 Apr 2008 WO
WO-2008048586 Apr 2008 WO
WO-2008048587 Apr 2008 WO
WO-2008064254 May 2008 WO
WO-2008091320 Jul 2008 WO
WO-2008103175 Aug 2008 WO
WO-2008112078 Sep 2008 WO
WO-2008112078 Oct 2008 WO
WO-2008144693 Nov 2008 WO
WO-2008144695 Nov 2008 WO
WO-2008144697 Nov 2008 WO
WO-2008144698 Nov 2008 WO
WO-2008153689 Dec 2008 WO
WO-2008153819 Dec 2008 WO
WO-2009016636 Feb 2009 WO
WO-2009032399 Mar 2009 WO
WO-2009032400 Mar 2009 WO
WO-2009035759 Mar 2009 WO
WO-2009088983 Jul 2009 WO
WO-2009089028 Jul 2009 WO
WO-2009089029 Jul 2009 WO
WO-2010111505 Sep 2010 WO
WO-2011014704 Feb 2011 WO
WO-2011068648 Jun 2011 WO
WO-2013016363 Jan 2013 WO
WO-2013184896 Dec 2013 WO
WO-2018085600 May 2018 WO
Non-Patent Literature Citations (37)
Entry
Application and File history for U.S. Appl. No. 11/755,480, filed May 30, 2007.
Application and File history for U.S. Appl. No. 13/465,570, filed May 7, 2012.
Application and File history for U.S. Appl. No. 14/187,414, filed Feb. 24, 2014.
Application and File history for U.S. Appl. No. 15/830,415, filed Dec. 4, 2017.
Application and File history for U.S. Appl. No. 16/507,380, filed Jul. 10, 2019.
Application and File history for U.S. Appl. No. 11/685,617, filed Mar. 13, 2007.
Application and File history for U.S. Appl. No. 15/266,468, filed Sep. 15, 2016.
Application and File history for U.S. Appl. No. 13/800,453, filed Mar. 13, 2013.
Boi I, et al., “Impact of Smoking on the Metabolic Action of Subcutaneous Regular Insulin in Type 2 Diabetic Patients,” Horm. Metab. Res., vol. 37, 2005, pp. 445-449.
Chase, et at., “The Use of Insulin Pumps With Meal Bolus Alarms in Children With Type 1 Diabetes to Improve Glycemic Control,” Diabetes Carem, vol. 29, No. 5, May 2006, pp. 1012-1015.
“Compare Insulin Pump for Diabetes,” Printed from www.diabetesnet.com/diabetes-technology/insulin-pump-models.php, Jun. 18, 2009, 4 pages.
Examination Report for EP Application No. 14775822.1, dated Jan. 4, 2019, 4 pages.
Extended European Search Report for Application No. 14775822.1, dated Nov. 21, 2016, 9 pages.
International Preliminary Reporton Patentability for Application No. PCT/US2008/002536, dated Sep. 15, 2009, 9 pages.
International Preliminary Reporton Patentability for Application No. PCT/US2008/006801, dated Dec. 1, 2009, 9 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2008/002536 dated Sep. 4, 2008, 12 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2008/006449 dated Oct. 10, 2008, 17 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2008/006801, dated Oct. 30, 2008, 17 pages.
International Search Report and Written Opinion for PCT Application No. PCT/US2015/042881 dated Nov. 11, 2015, 11 pages.
Lehmann, et al., “Combining rule-based reasoning and mathematical modeling in diabetes care,” Artificial Intelligence in Medicine, vol. 6, 1994, pp. 137-160.
Hildebrandt P, “Subcutaneous Absorption of Insulin in Insulin-Dependent Diavetic patients. Influence of Species Physico-Chemical properties of Insulin and Physiological factors,” Danish Medical Bulletin, Aug. 1991, 10 pages.
Office Action dated Apr. 4, 2018 for European Application No. 14775822.1, 4 pages.
Office Action dated May 25, 2010 for European Application No. 08779626.4, 7 pages.
Office Action dated Apr. 7, 2010 for European Application No. 08767934.6, 3 pages.
Plougmann, et al., “DiasNe—a diabetes advisory system for communication and education via the internet,” International Journal of Medical Informatics, vol. 64, 2001, pp. 319-330.
Puckett, et al., “A model for multiple subcutaneous insulin injections developed from individual diabetic patient data,” vol. 269, 1995, p. E1115-E1124.
Smith Medical MD Inc., “Deltec Cozmo, Personalized Insulin Pump, Starting Guide,” http://web.archive.org/web/20041207133223/http://www.cozmore.com/Library/-upload/starting.sub.-guide.sub.-032004.pdf, XP002497833, Dec. 7, 2004, pp. 1-83.
Stapel E., “Converting Between Decimals, Fractions, and Percents,” Purplemath, 2006, 9 pages, Available at http://www.purplemath.com/modules/percents2.htm, 2006.
Trajanoski, et al., “Pharmacokinetic Model for the Absorption of Subcutaneously Injected Soluble Insulin and Monomeric Insulin Analogues,” Biomedizinische Technik, vol. 38, No. 9. Sep. 1, 1993, pp. 224-231.
Wach, et al., “Numerical Approximation of Mathematical Model for Absorption of Subcutaneously Injected Insulin,” Med & Biol. Eng & comput., vol. 33, 1995, pp. 18-23.
Walsh, et al., “Diabetes Technology-Concept 1: Super Bolus,” available at Diabetes Technology-Concept 1: Super Bolus available at http://www.diabetesnet.com/diabetes.sub.-technology/super.sub.--bolus.ph-p&gt, Sep. 17, 2007, 3 pages.
Walsh J., et al., “Select & Test Your Correction Factor,” Pumping Insulin, Fourth Edition, Chapter 13, 2006, 10 Pages.
Walsh J., et al., “Select & Test Your Basal Rates,” Pumping Insulin, Fourth Edition, Chapter 11, 2006, 30 pages.
Walsh J., et al., “Select and Test Your Carb Factor,” Pumping Insulin, Fourth Edition, Chapter 12, 2006, 32 pages.
Walsh J., et al., “Pumping Insulin: Everything you need for Success on a Smart insulin Pump,” Torrey Pines Press, San Diego, ISBN 1-884804-86-1, 2006, 3 pages.
wikipedia.com, “Wikipedia's definition for “basal rate”,” printed from wikipedia.com on Jun. 12, 2009, 1 page.
Wilinska, et al., “Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin,” IEEE Transactions on Biomedical Engineering, vol. 52, No. 1, Jan. 2005, pp. 3-12.
Related Publications (1)
Number Date Country
20190388015 A1 Dec 2019 US
Divisions (1)
Number Date Country
Parent 11755480 May 2007 US
Child 13465570 US
Continuations (3)
Number Date Country
Parent 15830415 Dec 2017 US
Child 16560555 US
Parent 14187414 Feb 2014 US
Child 15830415 US
Parent 13465570 May 2012 US
Child 14187414 US